RxDoctor Payments Data

Victor Marinescu, MD

Cardiovascular Disease · Naperville, ILNPI 1619130697

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Edwards Lifesciences at 56.7% of the total. Reporting peaked in 2024 at $15,453 and has fallen 82.2% since, to $2,758 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,298in general payments, 2019–2025

Across 418 payments — averaging $65.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$15K
  • Heartflow, Inc.$3K
  • Boston Scientific$2K
  • Abbott$1K
  • Novartis$949
  • Pfizer$799
  • plus $4K from 29 others
$210,371in research payments, 2019–2025

Across 13 payments — averaging $16,182 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Heartflow, Inc.$190K
  • Novartis$21K

What the payments were for

  • Consulting fees$11,82043%
  • Travel & lodging$4,12815%
  • Food & beverage$11,27441%
  • Education$760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,298 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$607,420
Medicare patients
1,727
Services billed
6,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$168,646
EntrestoSacubitril/Valsartan91$137,202
JardianceEmpagliflozin73$88,304
XareltoRivaroxaban74$80,902
Repatha SureclickEvolocumab80$72,179
FarxigaDapagliflozin Propanediol22$23,479
Metoprolol Succinate669$8,322
Atorvastatin Calcium505$4,843
Ezetimibe174$4,617
Losartan Potassium294$3,213
Rosuvastatin Calcium234$2,816
Amlodipine Besylate294$2,503
Lisinopril259$2,269
ClopidogrelClopidogrel Bisulfate177$1,709
Potassium Chloride88$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$799$168,646133 claims
NovartisEntresto$949$137,20291 claims
Boehringer IngelheimJardiance$458$88,30473 claims
Johnson & JohnsonXarelto$146$80,90274 claims
AstraZenecaFarxiga$135$23,47922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →